Fas-670A/G (rs1800682) polymorphism and digestive cancer risk in asians: A meta-analysis

Genetic Testing and Molecular Biomarkers

Volumn 18, Issue 7, 2014, Pages 482-488

  Yuan, Hai Peng ^a   Liu, Qing Dong ^b   Li, Gai Qin ^a   Cong, Yan Qun ^c  

^a Central Hospital of Tai'an City   (China)

^b Department of Emergency Tai'An City Hospital of Traditional Chinese Medicine   (China)

^c ZHEJIANG HOSPITAL   (China)

Author keywords

[No Author keywords available]

Indexed keywords

FAS ANTIGEN; TUMOR MARKER;

ALLELE; APOPTOSIS; ARTICLE; ASIAN; CANCER RISK; CANCER SUSCEPTIBILITY; CASE CONTROL STUDY; CELL PROLIFERATION; COMPARATIVE STUDY; DIGESTIVE SYSTEM CANCER; ESOPHAGUS CANCER; GENETIC ASSOCIATION; GENETIC VARIABILITY; HETEROZYGOTE; HOMOZYGOTE; HUMAN; LIVER CELL CARCINOMA; META ANALYSIS; SINGLE NUCLEOTIDE POLYMORPHISM; STOMACH CANCER; SYSTEMATIC REVIEW; CHINA; ETHNOLOGY; GASTROINTESTINAL NEOPLASMS; GENETICS; MOLECULAR EPIDEMIOLOGY; MUTATION;

ANTIGENS, CD95; CHINA; GASTROINTESTINAL NEOPLASMS; HUMANS; MOLECULAR EPIDEMIOLOGY; MUTATION; POLYMORPHISM, SINGLE NUCLEOTIDE; TUMOR MARKERS, BIOLOGICAL;

EID: 84904346056     PISSN: 19450265     EISSN: 19450257     Source Type: Journal    
DOI: 10.1089/gtmb.2014.0032     Document Type: Article

References (31)

1. Chen XB, Chen GL, Liu JN, et al. (2009) Genetic polymorphisms in STK15 and MMP-2 associated susceptibility to esophageal cancer in Mongolian population (Chinese). Chin J Prev Med 43:559-564.
2. Danial NN, Korsmeyer SJ (2004) Cell death: critical control points. Cell 116:205-219. (Pubitemid 38167313)
3. DerSimonian R, Laird N (1986) Meta-analysis in clinical trials. Control Clin Trials 7:177-188. (Pubitemid 17189972)
4. Evan GI, Vousden KH (2001) Proliferation, cell cycle and ap-optosis in cancer. Nature 411:342-348. (Pubitemid 32467043)
5. Gastman BR, Atarshi Y, Reichert TE, et al. (1999) Fas ligand is expressed on human squamous cell carcinomas of the head and neck, and it promotes apoptosis of T lymphocytes. Cancer Res 59:5356-5364. (Pubitemid 29504005)
6. Green DR, Droin N, Pinkoski M (2003) Activation-induced cell death in T cells. Immunol Rev 193:70-81. (Pubitemid 36688041)
7. Hayashino Y, Noguchi Y, Fukui T (2005) Systematic evaluation and comparison of statistical tests for publication bias. J Epidemiol 15:235-243. (Pubitemid 41715789)
8. Hsu PI, Lu PJ, Wang EM, et al. (2008) Polymorphisms of death pathway genes FAS and FASL and risk of premalignant gastric lesions. Anticancer Res 28:97-103.
9. Hu Y, Jin LY, Huang X, et al. (2011) Fas-670 gene polymorphism and gastric cancer risk in Qinhai province of China (Chinese). Shandong Yiyao 51:45-46.
10. Huang QR, Morris D, Manolios N (1997) Identification and characterization of polymorphisms in the promoter region of the human Apo-1/Fas (CD95) gene. Mol Immunol 34:577-582. (Pubitemid 27512871)
11. Ikehara SK, Ikehara Y, Matsuo K, et al. (2006) A polymorphism of C-to-T substitution at-31 IL1B is associated with the risk of advanced gastric adenocarcinoma in a Japanese population. J Hum Genet 51:927-933. (Pubitemid 44800736)
12. Jain M, Kumar S, Lal P, et al. (2007) Role of BCL2 (ala43thr), CCND1 (G870A) and FAS (A-670G) polymorphisms in modulating the risk of developing esophageal cancer. Cancer Detect Prev 31:225-232. (Pubitemid 47248152)
13. Jung YJ, Kim YJ, Kim LH, et al. (2007) Putative association of Fas and FasL gene polymorphisms with clinical outcomes of hepatitis B virus infection. Intervirology 50:369-376. (Pubitemid 350014921)
14. Kanemitsu S, Ihara K, Saifddin A, et al. (2002) A functional polymorphism in fas (CD95/APO-1) gene promoter associated with systemic lupus erythematosus. J Rheumatol 29:1183-1188. (Pubitemid 34601951)
15. Kim SS, Hong SJ, Ahn YG, et al. (2003) Apo-1/Fas (CD95) gene polymorphism in korean hepatocellular carcinoma patients. Korean J Physiol Pharmacol 7:29-31. (Pubitemid 36503331)
16. Lee SH, Shin MS, Park WS, et al. (1999) Alterations of Fas (Apo-1/CD95) gene in non-small cell lung cancer. Oncogene 18:3754-3760. (Pubitemid 29338508)
17. Lowe SW, Lin AW (2000) Apoptosis in cancer. Carcinogenesis 21:485-495. (Pubitemid 30137934)
18. Mantel N, Haenszel W (1959) Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst 22:719-748.
19. Nagata S, Golstein P (1995) The Fas death factor. Science 267:1449-1456.
20. O'Connell J, O'Sullivan GC, Collins JK, et al. (1996) The Fas counterattack: Fas-mediated T cell killing by colon cancer cells expressing Fas ligand. J Exp Med 184:1075-1082.
21. Rabinowich H, Reichert TE, Kashii Y, et al. (1998) Lymphocyte apoptosis induced by Fas ligand-expressing ovarian carcinoma cells. Implications for altered expression of T cell receptor in tumor-associated lymphocytes. J Clin Invest 101:2579-2588. (Pubitemid 28270452)
22. Suda T, Takahashi T, Golstein P, et al. (1993) Molecular cloning and expression of the Fas ligand, a novel member of the tumor necrosis factor family. Cell 75:1169-1178. (Pubitemid 24006113)
23. Sun T, Miao X, Zhang X, et al. (2004) Polymorphisms of death pathway genes FAS and FASL in esophageal squamous-cell carcinoma. J Natl Cancer Inst 96:1030-1036. (Pubitemid 39162646)
24. Viard-Leveugle I, Veyrenc S, French LE, et al. (2003) Frequent loss of Fas expression and function in human lung tumours with overexpression of FasL in small cell lung carcinoma. J Pathol 201:268-277. (Pubitemid 37258938)
25. Wang J, Gao J, Li Y, Zhao X, et al. (2013) Functional polymorphisms in FAS and FASL contribute to risk of squamous cell carcinoma of the larynx and hypopharynx in a Chinese population. Gene 524:193-196.
26. Wang LH, Ting SC, Chen CH, et al. (2010) Polymorphisms in the apoptosis-associated genes FAS and FASL and risk of oral cancer and malignant potential of oral premalignant lesions in a Taiwanese population. J Oral Pathol Med 39:155-161.
27. Wang M, Wu D, Tan M, et al. (2009) FAS and FAS ligand polymorphisms in the promoter regions and risk of gastric cancer in Southern China. Biochem Genet 47:559-568.
28. Yang M, Sun T, Wang L, et al. (2008) Functional variants in cell death pathway genes and risk of pancreatic cancer. Clin Cancer Res 14:3230-3236.
29. Zhang J, Liu Q, Mao HT (2009) Analyzing of Fas-670 gene polymorphism in hepatocarcinoma (Chinese). Chin J Hepatol 17:630-631.
30. Zhou RM, Wang N, Chen ZF, et al. (2010) Polymorphisms in promoter region of FAS and FASL gene and risk of cardia gastric adenocarcinoma. J Gastroenterol Hepatol 25:555-561.
31. Zhu Q, Wang T, Ren J, et al. (2010) FAS-670A/G polymorphism: A biomarker for the metastasis of nasopharyngeal carcinoma in a Chinese population. Clin Chim Acta 411:179-183.